OPT Opthea Ltd.: EV/EBITDA Multiple

The pricing characteristics on the GURU.Markets platform, where the EV/EBITDA ratio is , complement the data regarding sustainable drug development and bioethical compliance at Opthea Limited (OPT). Opthea Limited (OPT) minimizes risks by developing a therapy to combat retinal degeneration in the elderly. However, business success depends on the final test results of the key drug, which creates a high probability of sharp price volatility.

OPT Opthea Ltd.: Total Company Value to Operating Income Before Depreciation Ratio in the range 07/04/2022 - 11/10/2026

Financial and market metric breakdowns for opthea.com (OPT)

- stock price and consensus target price:

Stock Quotes Opthea Ltd.|OPT - Average Forecast Price

- company stock capitalization data:

Market Capitalization Opthea Corp|OPT - Total Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Opthea|OPT - Book Valuation of Business|Market Value to Book Value Ratio opthea.com|OPT - Company Assets

- debt and liquidity data:

- business earnings and investment ratios data:

OPT - Net Profit|Future Profit Opthea Limited|OPT - Company Value to Net Income|Future Price to Earnings Opthea Limited|OPT - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Opthea Corp|OPT - Operating income before deduction of amortization|Earnings per share for the last twelve months Opthea|OPT - Net earnings per share for the last 12 months|Quarterly EPS earnings growth opthea.com|OPT - Expected net earnings per share growth this year|Expected earnings per share growth for next year Opthea Limited

General company analysis:Opthea Ltd. OPT

The EV/EBITDA multiple compares the total enterprise value of a business, including net debt, with its operating profit before taxes, depreciation, and amortization. By analyzing the dynamic EV/EBITDA value of a company, an investor determines the payback period for assets excluding financial leverage. For Opthea Limited (OPT), this indicator is critical as it reflects the market valuation of sozinibercept's potential in AMD therapy relative to current operating expenses within the biopharmaceutical sector.

Key competitors

Alcon Vision - Enterprise Value to EBITDA Ratio|Bausch Health (BLCO) - Company Value to EBITDA|Glaukos Corporation - EV/EBITDA Multiple|Company Value to EBITDA apellis.com|Belite Bio Corp (BLTE) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|OCUL - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harrow Health|Company Value to EBITDA Viridian Corp VRDN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LENZ Therapeutics, Inc. (LENZ)|OCS: Company Value to Operating Income Before Depreciation Ratio|EyePoint Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio KOD (Kodiak Sciences Inc)|Aldeyra - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation KALA (KALA BIO, Inc.)|IRD: EV/EBITDA Multiple|Company Value to EBITDA OKYO Pharma (OKYO)|ADVM (Adverum Biotechnologies Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Outlook Therapeutics Inc|Enterprise Value to EBITDA Ratio CLSD (Clearside)|NBY (novabay.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kiora Pharmaceuticals, Inc. KPRX|Alimera Sciences Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Eyenovia Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Guardion Health Sciences, Inc. GHSI|Ocuphire (OCUP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization